Premium Nahrungsergänzungsmittel | artgerecht

Avocado Soybean Unsaponifiables (ASU) - Effects & Use

Avocado Soybean Unsaponifiables (ASU) is a natural plant extract derived from avocado and soybean oils, used to support joint health and relieve symptoms of osteoarthritis.

Regular tips about health Regular tips about health

Things worth knowing about "Avocado Soybean Unsaponifiables"

Avocado Soybean Unsaponifiables (ASU) is a natural plant extract derived from avocado and soybean oils, used to support joint health and relieve symptoms of osteoarthritis.

What are Avocado Soybean Unsaponifiables?

Avocado Soybean Unsaponifiables (ASU) are natural plant extracts derived from the unsaponifiable fractions of avocado oil and soybean oil. Unsaponifiable fractions are the components of an oil that cannot be broken down through saponification (a chemical reaction with an alkali). These fractions are rich in bioactive compounds including phytosterols, triterpenes, tocopherols (vitamin E compounds), and fatty alcohols. The standard ratio used in therapeutic preparations is 1 part avocado extract to 2 parts soybean extract.

Mechanism of Action

ASU exerts its effects through multiple biological pathways that collectively support joint health:

Inhibition of pro-inflammatory cytokines: ASU reduces the production of inflammatory mediators such as interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-α), which play a central role in cartilage degradation.
Inhibition of matrix metalloproteinases (MMPs): MMPs are enzymes responsible for breaking down the cartilage matrix. ASU inhibits their activity and may thereby slow the progression of cartilage loss.
Stimulation of collagen synthesis: ASU promotes the production of type II collagen and aggrecan by chondrocytes (cartilage cells), which are key structural proteins of joint cartilage.
Suppression of COX-2-mediated prostaglandin synthesis: Similar to non-steroidal anti-inflammatory drugs (NSAIDs), but without their typical side effects, ASU modulates inflammatory signaling pathways.

Medical Use

ASU is primarily used in the treatment and supportive management of osteoarthritis (degenerative joint disease), particularly for:

Knee osteoarthritis (gonarthrosis)
Hip osteoarthritis (coxarthrosis)
Osteoarthritis of other joints

In France, ASU (marketed under the brand name Piasclédine) is approved as a prescription medication and is classified as a SYSADOA (Symptomatic Slow-Acting Drug for Osteoarthritis). In other countries, including Germany and the United States, ASU is primarily available as a dietary supplement.

Dosage

In clinical trials, ASU has most commonly been studied at a dose of 300 mg per day taken orally as a capsule. As a slow-acting agent, the effects typically become noticeable only after several weeks of consistent use. A treatment duration of at least 3 to 6 months is generally recommended to achieve the full therapeutic benefit.

Clinical Evidence

Several randomized, placebo-controlled clinical trials have evaluated the efficacy of ASU in knee and hip osteoarthritis:

Studies have demonstrated significant reductions in pain and functional disability compared to placebo.
The long-term ERADIAS trial examined the structure-modifying potential of ASU in hip osteoarthritis, with findings suggesting a reduction in joint space narrowing.
Both OARSI (Osteoarthritis Research Society International) and ESCEO (European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases) reference ASU in their treatment guidelines as a possible therapeutic option.

Safety and Side Effects

ASU is generally considered well tolerated. No serious adverse effects have been reported in clinical studies. Mild gastrointestinal complaints such as nausea or stomach discomfort may occasionally occur. Individuals with a known allergy to avocado or soy should avoid ASU. Use during pregnancy and breastfeeding is not recommended due to insufficient safety data.

Interactions

No clinically significant drug interactions have been identified to date. Nevertheless, the use of ASU should be discussed with a healthcare provider, especially for individuals taking anticoagulants (blood thinners) or other joint-targeted therapies.

References

Christensen R, Bartels EM, Astrup A, Bliddal H. - Symptomatic efficacy of avocado-soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials. - Osteoarthritis and Cartilage, 2008.
Maheu E, Cadet C, Marty M, et al. - Randomised, controlled trial of avocado-soybean unsaponifiable (Piasclédine) effect on structure modification in hip osteoarthritis: the ERADIAS study. - Annals of the Rheumatic Diseases, 2014.
Bannuru RR, Osani MC, Vaysbrot EE, et al. - OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. - Osteoarthritis and Cartilage, 2019.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.